US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry

US FDA’s recommendation against use of foreign-licensed reference products in clinical switching studies would result in procurement challenges and higher costs for biosimilar developers while also limiting where such studies could be conducted, some companies say.